Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Lynparza and Talzenna are targeted therapies known as PARP inhibitors. Both agents have received FDA approval for treating metastatic breast cancer caused by a BRCA mutation. BRACAnalysis CDx—a companion diagnostic test—received approval at the same time as the agents. The National Comprehensive Cancer Network (NCCN) has added
Lynparza as a preferred single agent treatment for people with advanced breast cancer and a BRCA mutation.
Talazoparib is a
PARP inhibitor that has not yet received FDA approval and is being studied in clinical trials. A large clinical trial known as the EMBRACA trial studied talazoparib for patients with metastatic breast cancer and a BRCA1 or BRCA2 mutation. Results showed that patients receiving talazoparib had on average 8.6 months of progression free survival compared to 5.6 months for patients receiving chemotherapy.
Based on these results, experts are hopeful that Talazoparib will receive
FDA approval for treating metastatic breast cancer caused by a BRCA mutation.
Research is now also looking at
PARP inhibitor effectiveness in additional settings including:
You can look for research studies enrolling patients with breast cancer by visiting FORCE's Research Study Search Tool.